Please assess the completion status of the following clinical trial:

Trial Title: Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* CML patients with failure or suboptimal response to imatinib therapy according to criteria established by the European Leukemia Net (ELN)~* Patients with grade II or higher adverse events.~* CML patients not suitable for stem cell transplantation.~Exclusion Criteria:~* Patients in blast crisis.~* Pregnant women~* Patients without a contraception method.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imatinib and nilotinib combination (Type: EXPERIMENTAL): All patients will receive treatment as follows: imatinib 100 mg tablets, 200 mg daily for 6 months; and nilotinib 150 mg capsule, 300 mg daily for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).